Some modern migraine medications may unexpectedly help protect vision and reduce the risk of developing glaucoma — one of the leading causes of irreversible blindness worldwide. That is the conclusion reached by researchers from the American Academy of Neurology. The study was published in the journal Neurology.
Scientists analyzed data from more than 73,000 people with migraine. One group of patients was treated with modern CGRP inhibitor drugs, while the other received older preventive migraine medications. Researchers found that people taking CGRP-targeting drugs had an approximately 25% lower risk of developing glaucoma.
Particular attention was drawn to the fact that the protective effect was observed only with so-called monoclonal antibody treatments — the drugs Erenumab, Fremanezumab, Galcanezumab, and Eptinezumab. Newer oral medications from the “gepant” class did not show the same effect.
Researchers believe the connection may be related to blood vessel function and inflammation in nervous tissue. Both migraine and glaucoma have long been associated with abnormalities in blood flow regulation in the brain and eyes. CGRP-targeting drugs act specifically on these mechanisms by regulating inflammatory processes and blood vessel constriction.
The authors emphasized that the study does not prove the drugs directly prevent glaucoma. For now, the findings show only a statistical association. Nevertheless, the results have attracted major interest because glaucoma remains one of the hardest eye diseases to detect early — vision can deteriorate for years with almost no symptoms.
Interest in CGRP medications has grown rapidly in recent years. Studies have shown that they not only reduce the number of migraine days, but often cause fewer side effects than older drugs. Some patients describe the treatments as “life-changing,” although many also complain about extremely high costs and insurance coverage issues.
Scientists believe the discovery could reshape understanding of both migraine and glaucoma. If future research confirms the findings, medications originally designed for headaches could unexpectedly become part of strategies to prevent vision loss.
Follow NEWS.am Medicine on Facebook and Twitter